Disciplines:

Nursing

Hours: 25 Contact Hours (25 Pharm Hours)
Item#: NBT25

 

Choose the best WS365 Online Nursing Membership for you:
Basic Membership – Access to 1-15 hour courses
PREMIUM Membership – Access to ALL nursing course

Pharmacology Bundle


Reg. Prices
Just $78.95
Item # NBT25
When available, the Online Course format is included with the hard copy, eBook, or audio book formats!

Cardiovascular disease is highly prevalent among the adult population. Nurses who are prescribing medications and those who care for these patients must maintain current knowledge of relevant medications.   

This CE bundle includes three high-level courses that also qualify for pharmacology hours: nursing pharmacology, cardiovascular pharmacology, and anticoagulant, antiplatelet, and thrombolytic therapies.

This product includes the following courses:
Click on the title to see more and read the course

Nursing Psychopharmacology

Price: $32.95  
Item # N1751  

Release Date: December 27, 2016

Expiration Date: December 31, 2019

 

Studies show that millions of people each year in the United States are affected by mental illness, however only about half of these receive treatment. Approximately 40 million people (18%) of the population suffer from an anxiety disorder annually. The prevalence of bipolar disorders is projected to be at 2.6% of the adult population and 11.2% for 13 to 18 year olds.  Depressive conditions are among the most frequently occurring mental health disorders in this country, 6.6% of adults aged 18 or older had a major depressive episode in 2014. The lifetime prevalence of schizophrenia is calculated to be about 1% of the population.

The National Center for Health Workforce Analysis estimates that the increase in supply of primary care physicians will fall short of the increased demand for primary care providers by 2025. Additionally, the NCHWA has estimated that the number of nurse practitioners providing primary care services will increase by 30% by the year 2020.

With the growing number of nurse practitioners entering the healthcare field as primary care providers, there is a demonstrated need for education on the ever-increasing number of new pharmaceutical agents available, to treat the wide spectrum of mental illness. This course addresses these needs by providing up-to-date information and a variety of case studies to illustrate practical application of the learning content.


This course should not be taken in conjunction with N1692 - Antidepressants, 2nd Edition, N1710 - Differentiating Antipsychotics: An Overview of Properties Impacting Drug Selection, or N1713 - Anxiolytics and Traditional Mood Stabilizers.


Kentucky APRNs - fuliflls pharmacology requirement

Disclosures
  • Courses must be completed on or before the expiration date noted in the course description above.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
  • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
Learning Outcomes

Course Objectives

  • Describe how neurons work, how they transmit information to each other, and the relevance of this information to psychotropic medications.
  • Discuss the pathophysiology of depression and appropriate treatment options for a patient with depression.
  • Identify the differences among antipsychotic medications and draft a therapeutic plan of care for a patient with schizophrenia.
  • Discuss pharmacotherapy for the treatment of anxiety disorders, and describe the patient teaching needs related to anxiolytic medications.
  • Explain the role of mood stabilizers in the management of bipolar disorders. Describe the safe and effective use of mood stabilizers in management of bipolar disorder, and describe the patient teaching needs related to medications for mood disorders.
Author Bio(s)

 

Charles F. Caley, BS Pharm, PharmD, BCPP, is Clinical Professor of Pharmacy Practice at the University of Connecticut School of Pharmacy and is a board-certified psychiatric pharmacist providing clinical and education services at the Institute of Living in Hartford, Connecticut. He received his BS in Pharmacy and PharmD degrees from the University of Rhode Island College of Pharmacy and then completed a 2-year specialty residency in psychiatric pharmacy at the Institute of Mental Health in Cranston, Rhode Island, and at Eastern State Hospital in Medical Lake, Washington. Dr. Caley is also an active provider of professional service to the psychiatric pharmacy profession. He is a founding member of the College of Psychiatric and Neurologic Pharmacists (CPNP) and served as the organization’s president in 2005-2006. Currently he is the Past President of the Board of Directors for the CPNP Foundation. Dr. Caley actively generates scholarship centered on psychotropic medications, and he has published in journals of pharmacy, psychiatry, and college health. In addition, he provides professional education presentations to audiences at the local, regional, and national level. Currently, Dr. Caley is working with others to transform the practice of pharmacy in Connecticut by being an active provider of comprehensive medication management services and also by leading a national effort to formally organize and recognize the practice efforts of those pharmacists in community mental health pharmacy settings.

Corey E. Scheer, RPh, BS Pharm, PharmD, BCPP, completed her BS Pharm and Doctor of Pharmacy degree at the University of Connecticut and then went on to complete a postgraduate year 1 residency at the University of Rochester Medical Center in Rochester, New York. From there, she completed a postgraduate year 2 residency specializing in psychiatric pharmacy at the Tuscaloosa VA Medical Center in Tuscaloosa, Alabama. After completing 2 years of residency, Dr. Scheer accepted a position as Clinical Assistant Professor of Pharmacy Practice at Western New England University College of Pharmacy, where she teaches psychiatry therapeutics and a case-based laboratory course, in addition to acting as a preceptor for final-year Doctor of Pharmacy students on clinical rotations at her practice site, Providence Behavioral Health Hospital. She is a board-certified psychiatric pharmacist. She has been teaching in the Doctor of Pharmacy program for 3 years.

 

Peer Reviewer Bio(s)

Kirstyn M. Kameg, DNP, PMHNP-BC, is a Professor of Nursing and is currently the coordinator of the Psychiatric Mental Health Nurse Practitioner program at Robert Morris University. She teaches doctoral level courses in psychopharmacology, neuroanatomy, and neurophysiology. She also maintains a private practice as a nurse practitioner treating adolescent and adult patients diagnosed with a variety of psychiatric diagnoses.  Anna Kabzinki Morin, PharmD, RPh, earned her PharmD at the University of Rhode Island in 1993 and has been a faculty member at the Massachusetts College of Pharmacy and Health Sciences (MCPHS) University School of Pharmacy- Worcester/Manchester since 2002. She is currently a professor in the department of Pharmacy Practice and is serving as the interim dean for the School of Pharmacy-Worcester/Manchester. Her teaching, scholarship, and clinical activities have focused on psychiatric illnesses, women’s health, drug interactions, and herbal and complementary alternative medicine. She is an active member of the College of Psychiatric and Neurologic Pharmacists.

Cardiovascular Pharmacology, 3rd Edition

Price: $26.95  
Item # N1744  

Release Date: December 27, 2016

Expiration Date: December 31, 2019

 

According to data from the Center for Disease Control, 610,000 people die from heart disease in the United States annually.  One in every four deaths is due to cardiovascular disease. There are also 12 million yearly visits to physician’s offices and close to 4 million hospital discharges for cardiovascular disease. Treatment of cardiovascular disease and monitoring for therapeutic efficacy and side effects of the drugs used require a sound knowledge of the pharmacology of these agents.

Ongoing education is needed to keep pace with these evolving changes and to equip nursing professionals with the necessary knowledge and skills to implement the most recent advances in treatment. Nurses have an important responsibility in caring for patients who are receiving these medications. Knowledge of cardiovascular medications, their effects on the body, and their administration; assessment of therapeutic and adverse effects; and patient education are essential. The purpose of this course is to provide an overview of cardiovascular pharmacology. With an ever-increasing number of patients living longer, quality nursing care for those receiving drugs for cardiovascular disease will make this knowledge critical. 

 

 

Kentucky APRNs - fulfills pharmacology requirement

 

 

Disclosures
  • Courses must be completed on or before the expiration date noted in the course description above.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
  • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
Learning Outcomes

Course Objectives

  • Recall the basic structures of the heart and their physiological functions.
  • Discuss ways medications are used to regulate vascular tone and improve cardiac output.
  • Describe the key pharmacological agents used to prevent and treat ischemic heart disease and cardiac rhythm disturbances.
Author Bio(s)

 

David S. Roffman, BS Zoology, BS Pharmacy, PharmD, BCPS, AQ Cardiology, is professor emeritus at the School of Pharmacy, University of Maryland. Dr. Roffman taught much of the cardiovascular therapeutics curriculum in both the didactic and experiential portions of the curriculum during his 45-year tenure at the school. He was recognized as Teacher of the Year on six occasions by students or faculty at the school, and in 2010, he was honored as Teacher of the Year for Founders Week at the University of Maryland Baltimore Campus. In addition to his efforts at the School of Pharmacy, Dr. Roffman taught in the Cardiology Module of the Pathophysiology, Pharmacology, and Therapeutics course at the University of Maryland School of Medicine as well as the Nursing Pharmacology course at the School of Nursing. He served as the therapeutic consultant to the Cardiac Care Unit and the Progressive Care Cardiac Unit at the University of Maryland Medical System for more than 40 years. Dr. Roffman was one of the original 17 specialty cardiology pharmacy practitioners in the United States to receive added qualifications in cardiology by the Board of Pharmacy Specialties.

 

Peer Reviewer Bio(s)

Latanja L. Divens, DNP, APRN, FNP-BC, is an instructor of nursing in both the undergraduate and graduate nursing programs at Louisiana State University Health Sciences Center. Dr. Divens earned a Bachelor of Science degree in biology from Xavier University of Louisiana (1996) and a Bachelor of Science in nursing degree from Our Lady of Holy Cross College (2001). She also received her master’s degree in nursing as a family nurse practitioner (2007) and the Doctor of Nursing Practice degree (2012) from Loyola University New Orleans. She is board certified by the American Nurses Credentialing Center as a primary care family nurse practitioner (FNP) and has been in this role for 9 years. As an FNP, Dr. Divens has had extensive experience in the areas of family practice, nephrology, and gastroenterology. Her passion lies in caring for patients with chronic diseases and serving underserved populations.

Abir Kanaan, PharmD, RPh, is a professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences (MCPHS). She joined the university in 2005 after completing a postgraduate pharmacy practice residency at Umass Memorial Medical Center in Worcester, Massachusetts. Dr. Kanaan also holds an adjunct faculty position in the Department of Medicine at the University of Massachusetts Medical School. In addition, she is affiliated with the Meyers Primary Care Institute, where she is involved in several research projects pertaining to medication safety in the outpatient setting. Dr. Kanaan also serves as a codirector and preceptor for the pharmacy fellowship program in Medication Safety, Quality and Informatics at Saint Vincent Hospital in Worcester. Dr. Kanaan is also the Postgraduate Education Committee program coordinator for the Worcester and Manchester campuses at MCPHS. Dr. Kanaan’s practice site is Saint Vincent Hospital in the Coronary Intensive Care Unit. She also started and currently leads the hospital’s anticoagulation monitoring program. Dr. Kanaan was appointed vice chair of the Department of Pharmacy Practice in July 2016.

Anticoagulant, Antiplatelet, and Thrombolytic Therapies: Implications for Advanced Practice Nursing

Price: $32.95  
Item # N1752  

Release Date: December 27, 2016

Expiration Date: December 31, 2019

 

Cardiovascular disease (CVD) is the leading cause of death in the United States. Despite a decline in the death rate in 2013, nearly 1 in 3 deaths were attributed to CVD. Anticoagulant, antiplatelet, and thrombolytic medications are commonly utilized in the prevention and management of many common medical conditions, including cardiovascular disease (stable and unstable angina), ST-elevation myocardial infarction, percutaneous coronary interventions that include stent placement, cardiac dysrhythmias (atrial fibrillation), acute arterial occlusion, peripheral arterial disease, deep vein thrombosis, pulmonary embolism, and ischemic stroke.  

Evidence-based nursing practice requires that nurses have the necessary knowledge base to assure competent and safe nursing care. The Joint Commission (2012) addresses the issue of patient safety within the context of anticoagulation therapy in National Patient Safety Goal 03.05.01, which advises healthcare providers to “reduce the likelihood of patient harm associated with the use of anticoagulant therapy.”

This course provides information on oral anticoagulants, with an emphasis on the novel oral anticoagulants, parenteral anticoagulants, antiplatelets, and thrombolytics. Their indications for treatment of cardiovascular disorders including atrial fibrillation, venous thromboembolism, acute coronary syndrome, heparin induced thrombocytopenia, acute ischemic stroke, acute myocardial infarctions and acute pulmonary embolism is review. In addition, monitoring guidelines and patient counseling is discussed.  The need for healthcare providers to understand the pharmacokinetics, pharmacodynamics, and pharmacotherapeutic considerations is imperative to achieve optimal patient outcomes.

 

This course should not be taken in conjunction with N1712 - Parenteral Anticoagulants: Implications for Patient Management, N1718 - Oral Anticoagulant Therapy: Implications for Patient Management, N1743 - Antiplatelet Therapy: Implications for Advanced Practice Nursing, or N1749 - Thrombolytic Therapy: Implications for Advanced Practice Nursing.

Kentucky APRNs - fulfills pharmacology requirement

 

Disclosures
  • Courses must be completed on or before the expiration date noted in the course description above.
  • You must score 75% or higher on the final exam and complete the course evaluation to pass this course and receive a certificate of completion.
  • Through our review processes, Western Schools ensures that this course content is presented in a balanced, unbiased manner and is free from commercial influence. It is Western Schools’ policy not to accept commercial support.
  • All persons involved in the planning and development of this course have disclosed no relevant financial relationships or other conflicts of interest related to the course content.
Learning Outcomes

Course Objectives

  • Describe the pharmacokinetics and pharmacodynamics of the novel oral anticoagulants and be able to identify the most appropriate and safest agent for the management of thrombotic conditions.
  • Differentiate between the use of current parenteral anticoagulants in the acute care setting for patients with acute coronary syndrome, treatment and prevention of venous thromboembolism, and heparin induced thrombocytopenia to achieve to achieve optimal outcomes.
  • Identify the appropriate antiplatelet medications and monitoring through increased knowledge of platelet aggregation and understanding of the pharmacokinetics and pharmacodynamics of antiplatelet agents.
  • Explain the difference in the pharmacokinetics and pharmacodynamics of thrombolytic agents to achieve optimal outcomes for patients diagnosed with acute ischemic stroke, myocardial infarction, and pulmonary embolism.
Author Bio(s)

C. Michael White, PharmD, FCP, FCCP, is professor and chair of the University of Connecticut School of Pharmacy’s Department of Pharmacy Practice in Storrs, Connecticut, and codirector of the Health Outcomes, Policy, and Evidence Synthesis research group at University of Connecticut (UConn) and Hartford Hospital in Hartford, Connecticut, which houses one of only 13 Agency for Healthcare Research and Quality-Designated Evidence-Based Practice Centers. Dr. White received his BS in Pharmacy and Doctor of Pharmacy degrees from the Albany College of Pharmacy in Albany, New York, and completed a cardiovascular clinical pharmacology fellowship at Hartford Hospital in Hartford, Connecticut. Dr. White has published more than 150 peer-reviewed articles, including publications in JAMA, Annals of Internal Medicine, Circulation, and Lancet. His research has been selected for the American Society of Health Systems Pharmacists Drug Therapy Research Award and the American Association of Colleges of Pharmacy Lyman Award. He is an American College of Clinical Pharmacy Young Investigator of the Year recipient and fellow of the American College of Clinical Pharmacologists and American College of Clinical Pharmacists. He is a contributing editor to the Annals of Pharmacotherapy, is on the editorial board for Pharmacy Practice News, and hosts a once-weekly show called “Ask the Pharmacist” on FOX61 in Hartford, Connecticut.

Diana M. Sobieraj, PharmD, BCPS, earned her Doctor of Pharmacy degree from the University of Rhode Island and subsequently completed a pharmacy practice residency at Hartford Hospital/The University of Connecticut School of Pharmacy. After her training, Dr. Sobieraj joined the faculty at UCONN School of Pharmacy, where she has worked for the past 8 years. Currently, Dr. Sobieraj is an Assistant Professor in the Department of Pharmacy Practice in the tenure track. Her scholarly interests focus on comparative effectiveness and health outcomes research of anticoagulants and the treatment and prevention of thrombosis. Dr. Sobieraj has more than 40 publications in the peer-reviewed literature, including journals such as Annals of Internal Medicine, Journal of the American Geriatrics Society, International Journal of Cardiology, and Thrombosis Research. Dr. Sobieraj is a member of the American College of Clinical Pharmacy, the current Secretary/Treasurer of the American College of Clinical Pharmacy Health Outcomes PRN, and a member of the Community Advisory Panel of the American College of Clinical Pharmacy Practice-Based Research Network.

William L. Baker, PharmD, FCCP, FACC, BCPS-AQ Cardiology, is an Assistant Professor of Pharmacy Practice at the University of Connecticut (UConn) School of Pharmacy in Storrs, Connecticut. Dr. Baker received his BS in Pharmacy Studies and Doctor of Pharmacy (PharmD) degrees from the UConn School of Pharmacy in 2000 and 2002, respectively. After being in clinical practice for a number of years, he completed a 2-year cardiovascular pharmacology and outcomes research fellowship at Hartford Hospital in Hartford, Connecticut (2006-2008). He has been on faculty with the UConn School of Pharmacy since 2009. Dr. Baker is a member of a number of pharmacy and cardiology organizations, including the American College of Clinical Pharmacy, American Heart Association, and American College of Cardiology. His clinical experience has focused on caring for adult patients with advanced heart disease who require mechanical therapies or cardiac transplantation. He is the author of more than 100 peer-reviewed publications and frequently presents his research at national/ international pharmacy and cardiology conferences. Dr. Baker teaches cardiovascular pharmacology and therapeutics in the UConn School of Pharmacy and holds adjunct appointments as Assistant Professor with both the UConn School of Medicine and UConn Graduate School.

Leanne Henry Fowler, DNP, AGACNP-BC, CCRN, CNE, graduated with a baccalaureate of science in nursing degree from Southern University in Baton Rouge, Louisiana, and a doctorate in nursing practice (DNP) specializing in nursing education and as an adult/gerontology acute care nurse practitioner from the University of South Alabama in Mobile. She conducted a successful quality improvement project for her DNP project titled Preventing Oversedation in the Mechanically Ventilated Adult via Interprofessional Implementation of the RASS Tool. She has 15 years of critical care nursing experience, 8 years of nursing education experience, 2 years as a board-certified adult/gerontology acute care nurse practitioner in hospital medicine, and 6 months in infectious diseases. She is ranked as an instructor at the LSU Health Sciences Center’s School of Nursing, where she is the course coordinator for the critical care course in the baccalaureate program and the BSN to DNP academic coordinator for the Adult-Gerontology Acute and Emergency Care Nurse Practitioner concentration. She is an active member in several professional organizations, including the American Association of Nurse Practitioners (nationally, as well as in the state and local chapters), American Association of Critical-Care Nurses (nationally, as well as the local chapter), Society of Critical Care Medicine (nationally, as well as the regional chapter), National League for Nursing, National Organization of Nurse Practitioner Faculty, and the Epsilon Nu chapter of Sigma Theta Tau.

Peer Reviewer Bio(s)

Abir Kanaan, PharmD, RPh, is an associate professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences (MCPHS) University. She joined the university in 2005, after completing a postgraduate pharmacy practice residency at University of Massachusetts Memorial Medical Center in Worcester, Massachusetts. Dr. Kanaan also holds an adjunct faculty position in the Department of Medicine at the University of Massachusetts Medical School. She is affiliated with the Meyers Primary Care Institute, where she is involved in several research projects pertaining to medication safety in the outpatient setting.

Dr. Kanaan serves as a co-director and preceptor for the pharmacy fellowship program in Medication Safety, Quality and Informatics at Saint Vincent Hospital in Worcester. Dr. Kanaan is also the Postgraduate Education Committee Program Coordinator for the Worcester and Manchester campuses at MCPHS University. Dr. Kanaan’s practice site is Saint Vincent Hospital in the Coronary Intensive Care unit. She started and currently leads the hospital’s anticoagulation monitoring program.

Jason Cross, PharmD, is an Associate Professor of Pharmacy Practice at MCPHS University (Worcester/Manchester Campus). He completed his PharmD at the University of Rhode Island College of Pharmacy in 2001 and then completed a pharmacy practice residency at UMass Medical School/UMass Memorial Medical Center. Since 2002, he has been a faculty member at MCPHS, where he has maintained practice sites in ambulatory care, critical care, and adult internal medicine. Dr. Cross facilitates several courses within the Doctor of Pharmacy, Master of Physician Assistant, and Doctor of Physical Therapy programs. Dr. Cross currently practices adult internal medicine at Baystate Medical Center, Springfield, Massachusetts, and is the assistant director of the Pharmacy Practice Residency.

Amy Drew, PharmD, BCPS, is an Associate Professor with the Division of Pharmacy Practice, Preceptor for PGY 1 Pharmacy Residency Program at Mercy Hospital/Saint Louis College of Pharmacy in Saint Louis, Missouri, and Clinical Pharmacist in Ambulatory Care at Mercy Clinic Family Medicine in Saint Louis, Missouri. Dr. Drew earned her earned her BS in Biology from University of Illinois at Urbana-Champaign and her PharmD from Midwestern University in Glendale, Arizona. She completed her residency training at the John Cochran VA Medical Center in St. Louis, Missouri. Since then, she has had a full-time faculty appointment with responsibilities in teaching, lecture coordination, resident and student precepting, research, and clinical practice. Her practice and scholarship have focused primarily in the areas of anticoagulation, diabetes, osteoporosis, and teaching and learning within the advanced practice setting. She is an active member of the American College of Clinical Pharmacy and American Society of Health-Systems Pharmacists, and she is board certified in pharmacotherapy specialty.

Want more choices?
Want more choices?